SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

2/9/24 5:07:50 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NBTX alert in real time by email

SC 13G/A 1 d687377dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934*

(Amendment No. 3)

NANOBIOTIX S.A.

(Name of Issuer)

Ordinary Shares, €0.03 nominal value per share

(Title of Class of Securities)

63009J107**

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

**	This CUSIP number applies to the Issuer’s American Depositary Shares, evidenced by American Depositary Receipts, each representing one ordinary share of the Issuer.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 63009J107		13G


1		NAMES OF REPORTING PERSONS Invus Public Equities, L.P.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Bermuda


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 0
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 0
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0%
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

2


CUSIP No. 63009J107		13G


1		NAMES OF REPORTING PERSONS Invus Public Equities Advisors, LLC
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 0
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 0
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0%
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

3


CUSIP No. 63009J107		13G


1		NAMES OF REPORTING PERSONS Artal International S.C.A.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Luxembourg


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 0
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 0
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

4


CUSIP No. 63009J107		13G


1		NAMES OF REPORTING PERSONS Artal International Management S.A.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Luxembourg


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 0
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 0
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

5


CUSIP No. 63009J107		13G


1		NAMES OF REPORTING PERSONS Artal Group S.A.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Luxembourg


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 0
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 0
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

6


CUSIP No. 63009J107		13G


1		NAMES OF REPORTING PERSONS Westend S.A.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Luxembourg


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 0
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 0
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

7


CUSIP No. 63009J107		13G


1		NAMES OF REPORTING PERSONS Stichting Administratiekantoor Westend
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION The Netherlands


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 0
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 0
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

8


CUSIP No. 63009J107		13G


1		NAMES OF REPORTING PERSONS Mr. Amaury Wittouck
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Belgium


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5		SOLE VOTING POWER 0
				6		SHARED VOTING POWER 0
				7		SOLE DISPOSITIVE POWER 0
				8		SHARED DISPOSITIVE POWER 0


9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0
12		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

9

Item 1(a).

Name of Issuer:

Item 1(a).

Name of Issuer:

Nanobiotix S.A. (the “Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

60, rue de Wattignies, 75012 Paris, France

Item 2(a).

Name of Person Filing:

Item 2(b).

Address of Principal Business Office or, if none, Residence:

Item 2(c).

Citizenship:

Item 2(c).

Citizenship:

(i) Invus Public Equities, L.P. (“Invus Public Equities”)

750 Lexington Avenue, 30th Floor, New York, NY 10022

Citizenship: Bermuda limited partnership

(ii) Invus Public Equities Advisors, LLC (“Invus PE Advisors”)

750 Lexington Avenue, 30th Floor, New York, NY 10022

Citizenship: Delaware limited liability company

(iii) Artal International S.C.A. (“Artal International”)

Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

Citizenship: Luxembourg limited partnership

(iv) Artal International Management S.A. (“Artal International Management”)

Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

Citizenship: Luxembourg société anonyme

(v) Artal Group S.A. (“Artal Group”)

Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

Citizenship: Luxembourg société anonyme

(vi) Westend S.A. (“Westend”)

Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

Citizenship: Luxembourg société anonyme

(vii) Stichting Administratiekantoor Westend (the “Stichting”)

Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands

Citizenship: Netherlands foundation

(viii) Mr. Amaury Wittouck

Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

Citizenship: Belgium

The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”

Item 2(d).

Title of Class of Securities:

Ordinary Shares, €0.03 nominal value per share (the “Shares”)

Item 2(e).

CUSIP Number:

The CUSIP Number is 63009J107. This CUSIP applies to the American Depositary Shares (“ADSs”), evidenced by American Depositary Receipts, each representing one Share. No CUSIP has been assigned to the Shares.

10

Item 3.

If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

This Item 3 is not applicable.

Item 4.

Ownership.

(a) Amount beneficially owned:

As of December 31, 2023, the Reporting Persons no longer beneficially own any Shares.

(b) Percent of class:

As of December 31, 2023, the Reporting Persons no longer beneficially own any Shares.

(c) As of December 31, 2023, the number of shares as to which each of Invus Public Equities, Invus PE Advisors, Artal International, Artal International Management, Artal Group, Westend, the Stichting and Mr. Wittouck has:

(i) Sole power to vote or to direct the vote:

0

(ii) Shared power to vote or to direct the vote:

0

(iii) Sole power to dispose or to direct the disposition of:

0

(iv) Shared power to dispose or to direct the disposition of:

0

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of December 31, 2023 the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

This Item 6 is not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

This Item 7 is not applicable.

Item 8.

Identification and Classification of Members of the Group.

This Item 8 is not applicable.

Item 9.

Notice of Dissolution of Group.

This Item 9 is not applicable.

Item 10.

Certification.

Each of the Reporting Persons hereby makes the following certification:

11

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

12

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 9, 2024


INVUS PUBLIC EQUITIES, L.P.

By:		INVUS PUBLIC EQUITIES ADVISORS, LLC, its general partner

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		President

INVUS PUBLIC EQUITIES ADVISORS, LLC

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		President

ARTAL INTERNATIONAL S.C.A.

By:		ARTAL INTERNATIONAL
		MANAGEMENT S.A., its managing
		partner

By:		/s/ Anne Goffard
Name:		Anne Goffard
Title:		Managing Director

ARTAL INTERNATIONAL MANAGEMENT S.A.

By:		/s/ Anne Goffard
Name:		Anne Goffard
Title:		Managing Director

ARTAL GROUP S.A.

By:		/s/ Anne Goffard
Name:		Anne Goffard
Title:		Authorized Person

WESTEND S.A.

By:		/s/ Anne Goffard
Name:		Anne Goffard
Title:		Managing Director


STICHTING
ADMINISTRATIEKANTOOR
WESTEND

By:		/s/ Amaury Wittouck
Name:		Amaury Wittouck
Title:		Sole Member of the Board

MR. AMAURY WITTOUCK

By:		/s/ Amaury Wittouck

Get the next $NBTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NBTX

Date	Price Target	Rating	Analyst
8/28/2024	$12.00	Buy	Guggenheim
12/8/2023	$11.00	Outperform	Leerink Partners

More analyst ratings

$NBTX
Press Releases

Fastest customizable press release news feed in the world

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submissionAdded expert industry leaders to Supervisory Board, further strengthening support for the Company's long-term growth strategyNBTXR3 program update from pancreatic cancer study and lung cancer study with MD Anderson expected 4Q 2024 and 1H 2025, respectivelyUpdate on expansion of product portfolio to include disruptive nanotherapeutic platform Curadigm expected 4Q 2024€53.2 million in cash and cash equivalents as of September 30, 2024 with cash runway into 4Q 2025 PARIS and CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTI
11/12/24 2:30:00 AM ET
$NBTX
Biotechnology: Pharmaceutical Preparations
Health Care
NANOBIOTIX to Participate in Multiple Investor Conferences in November
~ Guggenheim's Inaugural Healthcare Innovation Conference, Nov 11-13 ~ ~ Stifel Healthcare Conference, Nov 18-19 ~ ~ Jefferies London Healthcare Conference, Nov 19-21 ~ PARIS and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences: Guggenheim's Inaugural Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 4pm ET / 10pm CETLocation: Boston, MAPresenters: Laurent Levy, Chief Exec
10/31/24 3:30:00 AM ET
$NBTX
Biotechnology: Pharmaceutical Preparations
Health Care
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune system before checkpoint therapySeveral clinical milestones expected over the next 12-18 months including updated data in pancreatic, and head and neck cancer, and initial data in esophageal and lung cancer€66.3 million in cash and cash equivalents as of June 30, 2024, with a cash runway extended into Q4 2025 PARIS and CAMBRIDGE, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand t
9/18/24 4:15:00 PM ET
$NBTX
Biotechnology: Pharmaceutical Preparations
Health Care

$NBTX
Leadership Updates

Live Leadership Updates

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr Colette Shen, MD, PhD and Dr Ari Rosenberg, MD, and Dr Jeffrey Bockman, PhD, will moderate the event. The KOLs will join Dr Sebastien Paris, PhD, from the Company to provide an in-depth review of NBTXR3 and the data recently presented at the
6/12/24 4:15:00 PM ET
$NBTX
Biotechnology: Pharmaceutical Preparations
Health Care
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023
PARIS and CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for half-year ending June 30, 2023, on Tuesday, September 26, 2023, after the close of the US market. This release will be followed by a conference on Wednesday, September 27, 2023, at 8:00 AM EDT / 2:00 PM CEST. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company's half-year results and provide an update on business activiti
9/19/23 4:15:00 PM ET
$NBTX
Biotechnology: Pharmaceutical Preparations
Health Care
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer
PARIS and CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the appointment of Louis Kayitalire, MD, as chief medical officer. Dr. Kayitalire brings an exceptional biopharmaceutical industry track record with proven success in the research, development, registration, and commercialization of therapeutics in oncology. "We are pleased to welcome Dr. Kayitalire to our executive leadership team at this pivotal moment for the development and commercialization of potential first-in-class radioenhancer NBTXR3," sa
9/5/23 4:15:00 PM ET
$NBTX
Biotechnology: Pharmaceutical Preparations
Health Care

Nanobiotix Announced New Data At ASCO 2924, Showing 48% ORR In Evaluable Anti-PD-1 Naïve Patients (n=25); 28% ORR In Evaluable Anti-PD-1 Resistant Patients (n=25) As Per RECIST 1.1
NANOBIOTIX (NASDAQ:NBTX) today announced new data from Study 1100, a US Phase 1 dose escalation and dose expansion study evaluating radiotherapy-activated NBTXR3 followed by anti-PD-1 immune checkpoint inhibitors (“ICIs”) as a second-or-later line (“2L+”) therapy for patients with advanced solid and metastatic tumors. These data were presented by Study 1100 Coordinating Investigator Colette Shen, MD, PhD, at the 2024 Annual Meeting of the American Society for Clinical Oncology (“ASCO 2024”). Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-
6/2/24 10:42:47 AM ET
$NBTX
Biotechnology: Pharmaceutical Preparations
Health Care
NANOBIOTIX To Present Of new Data From Phase 1 Immunotherapy Program At The 2024 ASCO Annual Meeting Followed By An Investor Conference Call
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, at ASCO 2024Following the ASCO presentation, Nanobiotix will host an investor event on Sunday, June 2nd at 12:00 PM EDT / 6:00 PM CEST to review the presented resultsPARIS and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with ca
5/28/24 4:21:55 PM ET
$NBTX
Biotechnology: Pharmaceutical Preparations
Health Care
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of XP Inc. (NASDAQ:XP) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter EPS results. XP posted quarterly earnings of 37 cents per share, missing market estimates of 40 cents per share. The company's quarterly sales came in at $818.79 million versus expectations of $784.08 million, according to data from Benzinga Pro. XP shares dipped 11.5% to $18.99 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Akoustis Technologies, Inc. (NASDAQ:AKTS) shares climbed 213.3% to $0.4254 after the company reportedly floated the probability of bankruptcy after losing a lawsuit against Qorvo. Barnes
5/22/24 1:28:08 PM ET
$ADI
$AKTS
$AULT
$BCG
Semiconductors
Technology
Telecommunications Equipment
Utilities

$NBTX
Financials

Live finance-specific insights

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; "ITT") who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment48% ORR in evaluable anti-PD-1 naïve patients (n=25); 28% ORR in evaluable anti-PD-1 resistant patients (n=25) as per RECIST 1.176% DCR in evaluable naïve patients; 68% DCR in evaluable resistant patients as per RECIST 1.1Preliminary review of survival data in ITT anti-PD-1 naïve patients (n=33) showed mPFS of 7.3 months and mOS of 26.2 monthsITT anti-PD-1 resistant patients (n=35) showed mPFS of 4.2 months and mOS of 7.8 monthsFollowing the ASCO presentation, Nanobiotix wi
6/2/24 10:00:00 AM ET
$NBTX
Biotechnology: Pharmaceutical Preparations
Health Care
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, at ASCO 2024Following the ASCO presentation, Nanobiotix will host an investor event on Sunday, June 2nd at 12:00 PM EDT / 6:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients wit
5/28/24 4:15:00 PM ET
$NBTX
Biotechnology: Pharmaceutical Preparations
Health Care
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
PARIS and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the first quarter of 2024. First Quarter Financial Updates Cash and Cash Equivalents: Based on the current operating plan and financial projections, Nanobiotix anticipates that the cash and cash equivalents of €58.9 million as of March 31, 2024, will fund its operations into Q3 2025 which is inclusive of the $20 million milestone we meanwhile received. Conference Call and
5/22/24 2:00:00 AM ET
$NBTX
Biotechnology: Pharmaceutical Preparations
Health Care